[A comparative randomized phase-II study of Xeloda (capecitabine) and paclitaxel in patients with breast cancer progressing after anthracycline antibiotics]

Autor:	V M, Moiseenko, S M, O'Reilly, D C, Dalbot, S, Van Belle, R J, Gordon, T, Griffin, B, Osterwalder
Rok vydání:	2000
Předmět:	Adult Antibiotics Antineoplastic Paclitaxel Australia Antineoplastic Agents Breast Neoplasms Middle Aged Antineoplastic Agents Phytogenic Deoxycytidine United States Europe Disease Progression Humans Female Fluorouracil Treatment Failure Neoplasm Metastasis Capecitabine Aged
Zdroj:	Voprosy onkologii. 46(3)
ISSN:	0507-3758
Popis:	A randomized study of the effectiveness of treatment with capecitabine (Xeloda) (22) and paclitaxel (taxol) (19) was carried out in breast cancer patients resistant to anthracycline antibiotic drugs. Capecitabine and paclitaxel showed comparable effectiveness, although the former appeared less toxic, particularly, in hematologic complication situations. Therefore, it may be administered to out-patients who previously received several courses of chemotherapy.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=pmid________::1b955f72496c4d861729203b3b7037a7 https://pubmed.ncbi.nlm.nih.gov/10976273 Zobrazit plný text záznamu